Current issues of RNAi therapeutics delivery and development.
about
Production and clinical development of nanoparticles for gene deliveryTowards a new era in medicine: therapeutic genome editingTargeting Microtubules for Wound RepairTechnologies for controlled, local delivery of siRNARescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNADeciphering fact from artifact when using reporter assays to investigate the roles of host factors on L1 retrotranspositionEfficient delivery of DNA into bovine preimplantation embryos by multiwall carbon nanotubessiRNA Delivery Strategies: A Comprehensive Review of Recent Developments.Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertensionEffect of surface properties on liposomal siRNA delivery.Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer modelsDNA/RNA heteroduplex oligonucleotide for highly efficient gene silencingEfficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome.Multistep, effective drug distribution within solid tumors.RNA Viruses and RNAi: Quasispecies Implications for Viral EscapeLonger-acting clotting factor concentrates for hemophilia.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicinesImaging-guided delivery of RNAi for anticancer treatment.A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy.Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.Stacking up CRISPR against RNAi for therapeutic gene inhibition.Tumor-targeted Delivery of Anti-microRNA for Cancer Therapy: pHLIP is Key.Therapeutic approaches for the delivery of TNF-α siRNA.The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications.Hydrophobic interactions between polymeric carrier and palmitic acid-conjugated siRNA improve PEGylated polyplex stability and enhance in vivo pharmacokinetics and tumor gene silencingA High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.Delivery Pathway Regulation of 3′,3″-Bis-Peptide-siRNA Conjugate via Nanocarrier Architecture Engineering.Optimized Solid-Phase-Assisted Synthesis of Oleic Acid Containing siRNA Nanocarriers.Effective cytoplasmic release of siRNA from liposomal carriers by controlling the electrostatic interaction of siRNA with a charge-invertible peptide, in response to cytoplasmic pH.Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.Precise redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes.RNA interference. Drugging RNAi.MiRAR-miRNA Activity Reporter for Living Cells.
P2860
Q26752803-C935458E-0A9E-4B04-8D5C-F13AD64BF06CQ26773287-8301732F-D2BE-4209-950C-FB9FAAF5CEC7Q28075978-A4342C58-0B96-4751-B582-58195D1F00DEQ28087657-AC056563-CEA5-4D8F-BCA2-EAE2FD9343A4Q28396399-66EAD51C-F5C7-4F39-A78D-CE5DA5DA273DQ28593628-E154A436-4E0D-4AD5-B828-09FA5FE79C23Q28829918-3C85D900-F12F-426F-8995-405CA68920A8Q33611947-3D76CD9B-1DC4-4633-9A57-F8A56AEA079AQ35689975-F4FF99B3-8B3F-4141-B566-C73113922AFDQ35770214-ACED8C51-5D5D-40A5-A85F-AC2CE8C13B3EQ36421379-72167F5B-6FD9-4400-8384-4246DCAD6D79Q37013417-6A1E8D65-9FBB-4D66-BBF8-4BE3346D0484Q37031903-472AECC4-048C-4A1E-ACA2-42D2DCE6DCFFQ37361853-AD92AD61-FCCA-4486-BF79-6EEB9604D88BQ38261634-B0F5E4D4-6EA4-486D-9C22-90479A511BC5Q38535397-37ACD752-2A2E-4598-9729-77C0EA5FBD06Q38543283-8B416E03-C321-40B6-99D6-3643E344FCBAQ38555082-4EE1F958-178E-40A6-B0A5-B7BA20861D24Q38626721-C7A68C24-DC9C-4F1C-BD7C-0FCF30C5AC5CQ38656763-84078BD3-8CC7-4593-BE71-39DED7D8B85FQ38674444-413B906E-C1EC-4451-85AC-6ADDA418E3E6Q38710046-25E73D0C-6FCE-4367-A447-15714FD336F0Q38749605-AE9AACA9-8060-4377-92FA-F2BE2190D877Q38775787-5D512C82-DD04-4E16-A3BA-49F292EB7839Q38792714-F18B8ECF-D2CB-4E6A-A619-59053D30AFF5Q38811165-FB676733-DC02-45DC-8DC4-731E4949C9FDQ39016320-157B0F23-B859-469E-ABEF-F8EC676DD052Q39210558-86AD44D9-0D32-4A4D-815F-D9DABB4BA12CQ39227810-1D98736D-EE4C-4671-9115-3225C555E5CBQ39297820-4386155B-E036-4374-8D02-8B27992EE3A8Q39779323-4DE8415D-4F52-4E04-8A83-1593F2CA439DQ40272499-AA5B4430-3F54-4CD4-A70B-9987CCAB78AAQ42048496-5D4BA1F8-6212-4B49-936B-0336142C1D68Q47160679-C70222DF-037B-4F8E-BCC2-4857E776C8EEQ48116928-4509EFAA-16C7-422B-9ED2-72929724180EQ50856169-F79745B8-E6B6-46ED-A374-C02D842F2EB2Q52390750-2799E555-9487-4B92-8392-FFCA4AB3781BQ52840762-653397E6-AEC9-4710-9EF4-E8847A5202E9Q55360325-A05006F7-7C03-48AE-A7A8-8976B5606886Q55603693-1ECC6C7F-3F81-4D60-AC59-79D674AB010C
P2860
Current issues of RNAi therapeutics delivery and development.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Current issues of RNAi therapeutics delivery and development.
@en
type
label
Current issues of RNAi therapeutics delivery and development.
@en
prefLabel
Current issues of RNAi therapeutics delivery and development.
@en
P1476
Current issues of RNAi therapeutics delivery and development.
@en
P2093
D Haussecker
P356
10.1016/J.JCONREL.2014.07.056
P407
P577
2014-08-09T00:00:00Z